Skip to search formSkip to main contentSkip to account menu

Influence of dose reduction of vincristine in R-CHOP on outcomes of diffuse large B cell lymphoma

VCR dose tended to be reduced compared with CPM and DXR in R-CHOP, and lower ARDI of cytotoxic agents and lower RDI of VCR could lead to poor prognosis in the treatment of DLBCL with R- CHOP.
View on Springer (opens in a new tab)

Changes in Central Venous Catheter Use in the Hematology Unit with the Introduction of Ultrasound Guidance and a Peripherally Inserted Central Venous Catheter

USG has become commonplace since its introduction and the landmark-based subclavian approach was largely replaced by PICC with USG in 2018, which can help improve success rates and safety profiles.
View PDF (opens in a new tab)

A prospective multicenter phase II study of intrabone marrow transplantation of unwashed cord blood using reduced‐intensity conditioning

It is suggested that the intrabone marrow‐CBT procedure without using ATG improves hematopoietic recovery and decreases the incidence of chronic GVHD, but does not decrease the probability of acute GV HD.
View on Wolters Kluwer (opens in a new tab)

Minimal Residual Disease in Autografts and Bone Marrow of Patients with Multiple Myeloma: 8-Color Multiparameter Flow Cytometry (EuroFlow-NGF) Vs. Next-Generation Sequencing

To compare the prognostic value of MRD detection in autografts and bone marrow (BM) cells using 8-color MFC and NGS, and also MRD levels between fresh and cryopreserved autografteds using NGF, a study enrolled 52 newly-diagnosed MM patients who underwent ASCT.
View via Publisher (opens in a new tab)

Paraneoplastic Opsoclonus-myoclonus Syndrome with Anti-Hu and Anti-SOX-1 Antibodies after Immune-checkpoint Inhibitor Treatment Combined with Chemotherapy in a Patient with Small-cell Lung Cancer

A 69-year-old man with advanced small-cell lung cancer achieved partial remission after 3 courses of immunochemotherapy that included atezolizumab. Ten days after the last treatment, he developed…
View PDF (opens in a new tab)

Hematologic Malignancies (HM)-Screen-Japan 01: A Mutation Profiling Multicenter Study on Patients with Acute Myeloid Leukemia

Evaluated the frequency and characteristics of cancer-related genomic alterations in patients with AML using a comprehensive genome profiling assay (F1H) and determine the quality of specimens used in gene analysis to evaluate the time-dependent changes in the genome profiles of patients administered FLT3 inhibitors, gilteritinib, and quizartinib for treating AML.
View via Publisher (opens in a new tab)

Interim Analysis of Hematologic Malignancies (HM)-Screen-Japan 01: A Mutation Profiling Multicenter Study of Patients with AML

The primary outcome was the frequency of each genomic alteration in leukemia using FoundationOne®Heme (F1H), which is a comprehensive genomic profile that applies next-generation sequencing.
View via Publisher (opens in a new tab)

Genomic Analysis Focusing on RUNX1-RUNX1T1 in Japanese Patients with AML: HM-Screen-Japan 01

This study revealed the importance of KIT mutations in patients with R/R AML with RUNX1-RUNX1T1 fusion gene, and that the KITmutations may be a promising therapeutic target for this population, and suggests that comprehensive genomic assays are highly useful in establishing precision medicine, even in this type of AML.
View via Publisher (opens in a new tab)

[Atypical onset of therapy-related acute promyelocytic leukemia after combined modality therapy including (89)Sr for metastatic breast cancer].

This is the first report describing acute promyelocytic leukemia after administration of (89)Sr, to the authors' knowledge, and with an atypical onset and progression.
View on PubMed (opens in a new tab)

Genomic Analysis of NPM1 Mutation and KMT2A(MLL)-Rearrangement/Amplification in Japanese Patients with Acute Myeloid Leukemia: Hematologic Malignancies (HM)-Screen-Japan 01

The major amino acid alteration of NPM1 was a frameshift mutation at the 288 th histidine (W288fs*12) and patterns of KMT2A(MLL)-rearrangement included MLL fusion and partial tandem duplication (PTD) in ten patients each.
View via Publisher (opens in a new tab)
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)